ELECSYS® HBEAG IMMUNOASSAY AND ELECSYS® PRECICONTROL HBEAG

Test, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)

FDA Premarket Approval P130015

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the elecsys hbeag immunoassay and elecsys precicontrol hbeag. This device is indicated for:elecsys hbeag immunoassaythe elecsys hbeag immunoassay is intended for the in vitro qualitative determination of hepatitis b e antigen (hbeag) in human serum or plasma (k2-edta, lithium or sodium heparin, and sodium citrate) in adult patients with symptoms of hepatitis or at risk for hepatitis b virus (hbv) infection. The assay results, in conjunction with other serological and clinical information, may be used for the laboratory diagnosis of individuals with acute or chronic hepatitis b or recovery from hepatitis b infection. The electrochemilumin-escence immunoassay eclia is intended for use on the modular analytics e170 analyzer. Elecsys precicontrol hbeag elecsys precicontrol hbeag is used for quality control of the elecsys hbeag immunoassay on the modular analytics e170 analyzer.

DeviceELECSYS® HBEAG IMMUNOASSAY AND ELECSYS® PRECICONTROL HBEAG
Classification NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantROCHE DIAGNOSTICS OPERATIONS INC
Date Received2013-05-30
Decision Date2014-03-14
Notice Date2014-03-31
PMAP130015
SupplementS
Product CodeLOM
Docket Number14M-0326
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address ROCHE DIAGNOSTICS OPERATIONS INC 9115 Hague Rd indianapolis, IN 46250
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P130015Original Filing
S016 2018-10-09 30-day Notice
S015 2018-04-17 Real-time Process
S014 2017-10-11 Real-time Process
S013 2017-09-15 Normal 180 Day Track
S012 2017-08-03 30-day Notice
S011 2017-07-18 30-day Notice
S010 2017-05-24 30-day Notice
S009 2016-12-20 Normal 180 Day Track No User Fee
S008 2016-10-26 30-day Notice
S007 2016-04-28 Normal 180 Day Track
S006 2016-02-16 30-day Notice
S005 2016-01-27 135 Review Track For 30-day Notice
S004 2015-10-07 30-day Notice
S003 2015-06-29 30-day Notice
S002 2014-10-16 Real-time Process
S001 2014-05-23 30-day Notice

NIH GUDID Devices

Device IDPMASupp
04015630935215 P130015 000
04015630934843 P130015 009

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.